PubMed Health⌕ Search

PubMed · 8829681

[Corticosteroids limit the decrease in blood flow velocity in the microvessels of the gastric submucosal layer during stress in rats].

Abstract

To evaluate the influence of stress and corticosteroids on blood flow velocity in gastric submucosal microvessels it was used intravital microfilming by means of a dark-field contact epiobjective. The plasma filled "gap" in the continuous erythrocyte flow were used as the markers to measure linear blood flow velocity. In unstressed rats the linear blood flow velocity was equal to 2.0 +/- 0.08 mm/sec (156 microvessels, 6.4 +/- 0.14 micron in diameter), calculated volume blood flow--(6.9 +/- 0.48) x 10(-5) microliters/sec. Stress (water immersion and restraint) led to a decrease of blood flow velocity in microvessels to more than double. A stress-induced decrease of blood flow velocity was more greater in rats with insufficient corticosteroid production. The linear velocity of blood flow of these rats was lowered to 0.6 +/- 0.06 mm/sec, volume blood flow to (1.6 +/- 0.21) x 10(-5) microliters/sec. Replacement corticosterone therapy increased the blood flow velocity. It was concluded that stress decreases blood flow in microvessels of gastric submucosa. The results revealed that glucocorticoids take part in normalization of blood flow of gastric microvessels during stress and this action can provide antiulcerogenic effect of corticosteroids which was shown by us previously.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L P Filaretova, Iu I Levkovich, N A Mal'tsev. 1996. [Corticosteroids limit the decrease in blood flow velocity in the microvessels of the gastric submucosal layer during stress in rats].. https://pubmed.ncbi.nlm.nih.gov/8829681/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.

Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.

Adrenal Cortex Hormones↗

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.

Although the calcineurin inhibitors (CNI) cyclosporine (CsA) and tacrolimus are highly effective immunosuppressants, they are associated with serious side effects. There is great interest in immunosuppressive regimens that permit reduction or elimination of CNIs, while maintaining adequate immunosuppression and acceptable acute rejection rates. Patients (n = 536) receiving their first renal allograft were randomized to one of three immunosuppressant regimens: daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low-dose CsA (target trough levels of 50-100 ng/mL), weaned from month 4 and withdrawn by month 6; daclizumab, MMF, CS and low-dose CsA; or MMF, CS and standard-dose CsA. Mean GFR 12 months after transplantation (primary end point) was not statistically different in the CsA withdrawal and low-dose CsA groups (both 50.9 mL/min/1.73 m(2)) vs. the standard-dose CsA group (48.6 mL/min/1.73 m(2)). At 12 months, the incidence of biopsy-proven acute rejection was significantly higher in the CsA withdrawal group (38%) vs. the low- or standard-dose CsA groups (25.4% and 27.5%, respectively; p < 0.05). In summary, a regimen of continuous low-dose CsA with MMF, CS and daclizumab induction is a clinically safe and effective immunosuppressive regimen in renal transplant recipients.

Adrenal Cortex Hormones↗